Gennova Biopharmaceuticals

India's Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, a person with direct knowledge of the matter told Reuters.

Pharmaceutical firm Gennova Biopharmaceuticals' COVID-19 vaccine, the first homegrown mRNA-based shot, was found to be safe and effective in an early-stage study, the government said on Tuesday.

Pune-based Gennova Biopharmaceuticals has initiated the enrolment of volunteers for Phase 1/2 clinical trials for its mRNA vaccine candidate HGCO19, said the Department of Biotechnology, which provided seed funding for its development, on Tuesday.

An anti-Coronavirus vaccine being developed by the Pune-based company, Gennova, has become the first indigenous mRNA candidate to have received approval to initiate human clinical trial, a central government statement has said.

The Drugs Controller General of India (DCGI) on Wednesday granted conditional permission for phases 1 and 2 human clinical trial of the COVID-19 vaccine candidate developed by the Pune-based Gennova Biopharmaceuticals Ltd in collaboration with HDT, USA, officials said.

Ambassadors and envoys from 100 countries will visit Serum Institute of India and Gennova Biopharmaceuticals Ltd in Pune on December 4 amid the coronavirus outbreak and race for vaccines to combat the infection, a senior official said on Tuesday.

India's Gennova Biopharmaceuticals is working on an Omicron-specific COVID-19 vaccine candidate that could be ready in a month or two, a person with direct knowledge of the matter told Reuters.

Pharmaceutical firm Gennova Biopharmaceuticals' COVID-19 vaccine, the first homegrown mRNA-based shot, was found to be safe and effective in an early-stage study, the government said on Tuesday.

Pune-based Gennova Biopharmaceuticals has initiated the enrolment of volunteers for Phase 1/2 clinical trials for its mRNA vaccine candidate HGCO19, said the Department of Biotechnology, which provided seed funding for its development, on Tuesday.

An anti-Coronavirus vaccine being developed by the Pune-based company, Gennova, has become the first indigenous mRNA candidate to have received approval to initiate human clinical trial, a central government statement has said.

The Drugs Controller General of India (DCGI) on Wednesday granted conditional permission for phases 1 and 2 human clinical trial of the COVID-19 vaccine candidate developed by the Pune-based Gennova Biopharmaceuticals Ltd in collaboration with HDT, USA, officials said.

Ambassadors and envoys from 100 countries will visit Serum Institute of India and Gennova Biopharmaceuticals Ltd in Pune on December 4 amid the coronavirus outbreak and race for vaccines to combat the infection, a senior official said on Tuesday.